Clinical Trial Update: A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria [Phase 2]

View source ↗

Summary

A Phase 2 trial of subcutaneous lirentelimab (AK002) in chronic spontaneous urticaria was terminated, with results posted on 2024-09-27.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• lirentelimab (AK002) (lirentelimab)

Snippet

Sponsor: Allakos Inc. | Conditions: Chronic Spontaneous Urticaria | Phase 2 | Status: TERMINATED | Results posted: 2024-09-27